ELIGARD® has demonstrated a well-tolerated safety profile1-3

Most commonly reported treatment-related adverse events*1-3

Please refer to the Summary of Product Characteristics of Eligard for additional information.

Pharmacovigilance website

References+

  • 1. Perez-Marreno R, et al. Clin Ther 2002; 24: 1902-14.
  • 2. Chu FM, et al. J Urol 2002; 168: 1199-203. 3.Crawford ED, et al. J Urol. 2006; 175: 533-6.